Governance & Derivative
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI)
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI).
On August 6, 2021, the Company disclosed the receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the application for its drug candidate, ROLONTIS, that highlighted manufacturing deficiencies and indicated that a reinspection of the Company’s manufacturing facility would be necessary.
Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing.
KSF’s investigation is focusing on whether Spectrum’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
If you have information that would assist KSF in its investigation, or have been a long-term holder of Spectrum shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn (email@example.com), or fill out the form on this page.